<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-1249</journal-id>
<journal-title><![CDATA[Archivos de Pediatría del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Pediatr. Urug.]]></abbrev-journal-title>
<issn>1688-1249</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-12492025000301314</article-id>
<article-id pub-id-type="doi">10.31134/ap.96.31</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de atenolol para el tratamiento de un hemangioma infantil: caso clínico de interés]]></article-title>
<article-title xml:lang="en"><![CDATA[Use of atenolol for the treatment of infantile hemangioma: clinical case of interest]]></article-title>
<article-title xml:lang="pt"><![CDATA[Uso de atenolol para tratamento de hemangioma infantil: caso clínico de interesse]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quagliata]]></surname>
<given-names><![CDATA[Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[Agustina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Mariela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,UDELAR Facultad de Medicina Cátedra Dermatología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,UDELAR Facultad de Medicina Cátedra Dermatología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,UDELAR Facultad de Medicina Cátedra Dermatología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>96</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-12492025000301314&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-12492025000301314&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-12492025000301314&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Los hemangiomas infantiles (HI) son los tumores benignos más frecuentes en la infancia, suelen aparecer durante las primeras semanas de vida y siguen una trayectoria natural característica de proliferación e involución. La mayoría de los HI no necesitan intervención resolviéndose espontáneamente, pero aquellos pocos casos que presentan complicaciones o se encuentran en zonas de riesgo pueden requerir tratamiento. El propanolol se utiliza como terapia de primera línea. Algunos pacientes desarrollan efectos adversos indeseados durante el tratamiento (hiperactividad bronquial, hipoglicemia, trastornos del sueño). El atenolol ha demostrado ser una opción terapéutica con buen perfil de mejoría y seguridad como alternativa a pacientes que presentan efectos adversos al propanolol. Presentamos el caso de un lactante con un HI tratado con éxito con atenolol.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary: Infantile hemangiomas (IH) are the most common benign tumors of childhood. They typically appear within the first weeks of life and follow a natural course of proliferation and involution. Most IHs resolve spontaneously without intervention; however, a small number of cases with complications or located in high-risk areas may require treatment. Propranolol is the first-line therapy, but some patients experience undesirable side effects during treatment (bronchial hyperactivity, hypoglycemia, sleep disturbances). Atenolol has emerged as a therapeutic alternative with a favorable safety and efficacy profile for patients who develop adverse effects to propranolol. We report the case of an infant with IH successfully treated with atenolol.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: Os hemangiomas infantis (HI) são os tumores benignos mais comuns na infância. Geralmente surgem durante as primeiras semanas de vida e seguem uma trajetória natural característica de proliferação e involução. A maioria dos HI não requer intervenção e resolve-se espontaneamente. No entanto, os poucos casos que apresentam complicações ou estão localizados em áreas de alto risco podem necessitar de tratamento. O propranolol é usado como terapia de primeira linha. Alguns pacientes desenvolvem efeitos adversos indesejados durante o tratamento (hiper-atividade brônquica, hipoglicemia, distúrbios do sono). O atenolol demonstrou ser uma opção terapêutica com bom perfil de melhora e segurança como alternativa para pacientes que apresentam efeitos adversos do propranolol. Apresentamos o caso de um lactente com HI tratado com sucesso com atenolol.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hemangioma]]></kwd>
<kwd lng="es"><![CDATA[Atenolol]]></kwd>
<kwd lng="es"><![CDATA[Lactante]]></kwd>
<kwd lng="en"><![CDATA[Hemangioma]]></kwd>
<kwd lng="en"><![CDATA[Atenolol]]></kwd>
<kwd lng="en"><![CDATA[Infant]]></kwd>
<kwd lng="pt"><![CDATA[Hemangioma]]></kwd>
<kwd lng="pt"><![CDATA[Atenolol]]></kwd>
<kwd lng="pt"><![CDATA[Lactente]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>International Society for the Study of Vascular Anomalies</collab>
<source><![CDATA[ISSVA Classification]]></source>
<year>2024</year>
<publisher-loc><![CDATA[Milwaukee, WI ]]></publisher-loc>
<publisher-name><![CDATA[ISSVA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sebaratnam]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wargon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infantile hemangioma Part 1: epidemiology, pathogenesis, clinical presentation and assessment]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2021</year>
<volume>85</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1379-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ballona]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral atenolol for infantile hemangioma case series of 46 infants]]></article-title>
<source><![CDATA[Actas Dermosifiliogr (Engl Ed)]]></source>
<year>2020</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheirif]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Novelo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Orozco]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sáez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infantile hemangioma an update in the topical and systemic treatments]]></article-title>
<source><![CDATA[Bol Med Hosp Infant Mex]]></source>
<year>2019</year>
<volume>76</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>167-75</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Xiang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of propranolol in the treatment of infantile haemangiomas an update on potential mechanisms of action]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2015</year>
<volume>172</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ábarzúa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Navarrete]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Heusser]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Retamal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zegpi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atenolol versus propranolol for the treatment of infantile hemangiomas a randomized controlled study]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2014</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1045-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raphael]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Breugem]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vlasveld]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[de Graaf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Slieker]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pasmans]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas : a cohort study]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2015</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>465-72</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Starkey]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Shahidullah]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Propranolol for infantile haemangiomas a review]]></article-title>
<source><![CDATA[Arch Dis Child]]></source>
<year>2011</year>
<volume>96</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>890-3</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pattanshetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mahalmani]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sarma]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral atenolol versus propranolol in the treatment of infantile hemangioma a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Indian Assoc Pediatr Surg]]></source>
<year>2022</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>279-86</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Sociedad Argentina de Dermatología</collab>
<source><![CDATA[Consenso sobre hemangiomas infantiles 2016]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[SAD]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA Otolaryngol Head Neck Surg]]></source>
<year>2021</year>
<volume>147</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>599-607</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
